Multiple Myeloma

Findings from a second phase II clinical trial have demonstrated impressive signs of clinical activity with the anti-CD38 monoclonal antibody daratumumab as a monotherapy for patients with heavily pretreated multiple myelom.

The European Medicines Agency has accepted a marketing authorization application for ixazomib in combination with lenalidomide and dexamethasone for patients with relapsed/refractory multiple myeloma.

Peter Voorhees, MD, UNC Lineberger Comprehensive Cancer Center, discusses the future treatment paradigm for myeloma.

The FDA has broadened the approval of carfilzomib to include patients with relapsed multiple myeloma who have received at least one prior therapy.

A supplemental new drug application has been submitted for carfilzomib (Kyprolis) in combination with dexamethasone for patients with relapsed multiple myeloma following prior treatment with at least one therapy.

A new drug application has been submitted for the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma

Philip McCarthy, MD, explains the significance of the updated CALGB 100104 study results.

The landscape of therapeutic options for patients with myeloma at all phases of treatment has rapidly changed with the development of new drugs and targets.